Information Provided By: 
Fly News Breaks for December 6, 2019
NVS, GOSS
Dec 6, 2019 | 06:55 EDT
Cantor Fitzgerald analyst Eliana Merle initiated coverage of Gossamer Bio (GOSS) with an Overweight rating and $34 price target. The analyst sees a "compelling" setup into 2020. While the Luster data from Novartis (NVS) has significant stock moving potential for Gossamer, with upside potential of 75%-100% versus downside of 25%-50%, GB002 for pulmonary arterial hypertension could be a $2B peak sales opportunity with potential de-risking in the first half of 2020 "that deserves more focus," Merle tells investors in a research note.
News For GOSS;NVS From the Last 2 Days
